Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial

G. Wunderink, Richard; J. Giamarellos‐Bourboulis, Evangelos; Rahav, Galia; J. Mathers, Amy; Bassetti, Matteo; A. Vázquez, José; A. Cornely, Oliver; S. Solomkin, Joseph; Bhowmick, Tanaya; Bishara, Jihad; L. Daikos, George; Felton, Tim; José López Furst, María; Kwak, E.J.; Menichetti, Francesco; Oren, Ilana; Alexander, Elizabeth; C. Griffith, David; Lomovskaya, Olga; S. Loutit, Jeffery; Zhang, Shu; N. Dudley, Michael; S. Kaye, Keith

doi:10.1007/s40121-018-0214-1

Public

Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial

Published in Infectious Diseases and Therapy • Sep 30, 2018

Authors:

Richard G. Wunderink

Evangelos J. Giamarellos‐Bourboulis

Galia Rahav

Abstract

INTRODUCTION: Treatment options for carbapenem-resistant Enterobacteriaceae (CRE) infections are limited and CRE infections remain associated with high clinical failure and mortality rates, particularly in vulnerable patient populations. A Phase 3, multinational, open-label, randomized controlled tr...

Subject

Medicine

Tigecycline

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!